MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
7.10
-0.19
-2.61%
After Hours: 7.10 0 0.00% 19:39 09/25 EDT
OPEN
7.33
PREV CLOSE
7.29
HIGH
7.38
LOW
7.04
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
31.35
52 WEEK LOW
3.760
MARKET CAP
918.99M
P/E (TTM)
-1.8639
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALMS last week (0914-0918)?
Weekly Report · 6d ago
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 09/18 14:20
Weekly Report: what happened at ALMS last week (0907-0911)?
Weekly Report · 09/14 09:19
Alumis (ALMS), What Is Behind The Fresh Attention?
Simply Wall St · 09/11 20:22
Thursday 9/10 Insider Buying Report: ALMS, PRTS
NASDAQ · 09/10 14:44
Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)
TipRanks · 09/09 17:15
Alumis (ALMS) Is Down 49.1% After Mixed LUMUS Trial Data Reshapes Envudeucitinib’s Precision-Medicine Path
Simply Wall St · 09/07 19:28
Weekly Report: what happened at ALMS last week (0831-0904)?
Weekly Report · 09/07 09:18
More
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.